Kindler nominated for Time's Influentials list; Sanofi plant still closed after Italian quake;

> Pfizer CEO Jeff Kindler (photo) made Time's list of nominees for 2008's 100 Most Influential People; it's the first time Kindler has been among the nominees. Report

> A manufacturing facility operated by Sanofi-Aventis in Abruzzo, Italy, remains closed following the earthquake that claimed more than 280 lives earlier this month. Report

> South Africa's No.2 drug maker Adcock Ingram is willing to discuss its offering price in a potential $232.2 million buyout of Cipla Medpro, but will not necessarily sweeten its bid, a spokesman said. Report

> With the global pharmaceutical market likely to witness products worth $123 billion losing patents by 2012, the generics-driven Indian drugs industry could capture around $18.4 billion in new business, officials estimate. Report

> India's Cipla saw its shares fall in Mumbai trading after the Economic Times reported the FDA found deficiencies in its manufacturing processes. Report

> For Roche, getting its arms all around Genentech includes getting a chance to finally take a very close look at some of the biotech's in-house data on its drug prospects. Report

> Dendreon has been alternately hammered and smothered with love by market analysts as its cancer vaccine Provenge wound its way through Phase III. But the developer's sunny view of its Phase III data has triggered quite a bit of zigging and zagging as the analysts sought to keep up. Report

> Sunnyvale, CA-based Pharmacyclics has scored a $39.5 million development deal with France's Servier. Report

> BioMarck Pharmaceuticals says it has closed its Series C round with over $6.3 million in financing. The Research Triangle Park, NC-based company raised most of the capital through existing investors. Report

> At the Massachusetts Biotechnology Council meeting earlier this week, Governor Deval Patrick--introduced as the biotech industry's "best friend"--surprised attendees by using the platform to urge the industry to hire union members for construction jobs. Report

And Finally... UCLA researchers have provided strong new evidence linking at least some cases of Parkinson's disease to pesticide exposure. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.